Señales en vivo de FNCH | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States...

Stats
Volumen de hoy	53 317.00
Volumen promedio	47 069.00
Capitalización de mercado	3.69M
EPS	$0 ( 2024-03-28 )
Próxima fecha de ganancias	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0560 (2.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Smisek Jeffery A	Sell	1 600	Common Stock
2024-03-28	Smisek Jeffery A	Sell	6 642	Common Stock
2023-11-22	Smisek Jeffery A	Sell	1 470	Common Stock
2023-06-09	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)
2023-06-08	Blischak Matthew P.	Buy	962 899	Stock Option (right to buy)

INSIDER POWER
97.82
Last 84 transactions
Buy: 22 938 760 \| Sell: 28 923 806

Finch Therapeutics Group, Correlación

10 Correlaciones Más Positivas
ACET	0.917
VNDA	0.917
AFMD	0.914
COMT	0.91
GROM	0.903
EQRX	0.889
STRC	0.889
VRAY	0.886
KSPN	0.885
AYLA	0.883

10 Correlaciones Más Negativas
ROVR	-0.879
NVCN	-0.878
FTIV	-0.876
TIOAU	-0.873
XM	-0.873
ATVI	-0.873
BHAC	-0.868
IDLB	-0.867
APXI	-0.867
PAYA	-0.867

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Finch Therapeutics Group, Correlación - Moneda/Commodity

0.53
( weak )

0.35
( neutral )

0.00
( neutral )

0.35
( neutral )

0.48
( neutral )

0.36
( neutral )

Finch Therapeutics Group, Finanzas

Annual	2023
Ingresos:	$107 000
Beneficio Bruto:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2023
Ingresos:	$107 000
Beneficio Bruto:	$-1.41M (-1 320.56 %)
EPS:	$-46.59

FY	2022
Ingresos:	$861 000
Beneficio Bruto:	$-4.65M (-539.61 %)
EPS:	$-71.52

FY	2021
Ingresos:	$18.53M
Beneficio Bruto:	$18.53M (100.00 %)
EPS:	$-1.676

Financial Reports:

No articles found.

Finch Therapeutics Group,

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Actualizaciones en tiempo real para Finch Therapeutics Group, [FNCH]

Upcoming Earnings Alert